Linkedin
On June 8, 2017, 19 patients who benefitted from treatment with Abiomed’s Impella® heart pumps visited Washington, DC, to meet with elected officials and take part in a Congressional Briefing hosted by the MedTech Caucus, which supports development of innovative technology.
The patients in this group suffered from advanced heart failure or cardiogenic shock due to heart attacks, and benefitted from usage of Impella® technology, which is the only Food and Drug Administration-approved line of percutaneous heart pumps indicated for individuals with life-threatening conditions. As documented in clinical papers, heart recovery is the ideal option...
Heart Recovery Patients Advocate on Capital Hill for Lifesaving Technology
On June 8, 2017, 19 patients who benefitted from treatment with Abiomed’s Impella® heart pumps visited Washington, DC, to meet with elected officials and take part in a Congressional Briefing hosted by the MedTech Caucus, which supports development of innovative technology.
The patients in this group suffered from advanced heart failure or cardiogenic shock due to heart attacks, and benefitted from usage of Impella® technology, which is the only Food and Drug Administration-approved line of percutaneous heart pumps indicated for individuals with life-threatening conditions. As documented in clinical papers, heart recovery is the ideal option...